Literature DB >> 19225876

IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study.

Hong Ye1, Guo-ning Huang, Ping-hong Zeng, Li Pei.   

Abstract

OBJECTIVE: To study if luteal E(2) pre-treatment before GnRH antagonist protocol improves IVF/ICSI outcomes compared with standard long GnRH agonist protocol.
DESIGN: A prospective, randomized and controlled study.
SETTING: ART center of a state public hospital PATIENT(S): Two hundred twenty infertile women underwent IVF/ICSI treatments. INTERVENTION(S): Participants received oral Estradiol Valerate 4 mg/day preceding the IVF cycle from day 21 until day 2 of next cycle before GnRH antagonist protocol (E(2) pre-treatment group n=109) or received standard long GnRH agonist protocol as control group (n=111). MAIN OUTCOME MEASURE(S): Number of oocytes collected, MII oocytes, fertilization, implantation, live birth and early pregnancy rate, and hormone profiles. RESULT(S): E(2) pre-treatment exerted a significant suppressive effect on FSH but not LH secretion compared with basal FSH and LH levels. In E(2) pre-treatment group serum LH level was significantly higher during COH and serum P was also significantly higher on the day of HCG injection compared with control group. Five patients from E(2) pre-treatment group had elevated LH at all time (>or= 10 IU/L) and also a concomitantly high P (>1 ng/mL). Two of the five women achieved pregnancy but had early pregnancy loss. Overall, IVF/ICSI outcomes such as implantation, clinical pregnancy and live birth rates were similar between E(2) pre-treatment and control groups. CONCLUSION(S): Luteal E(2) pre-treatment before GnRH antagonist protocol significantly increases serum LH level and incidence rate of premature LH but no significant effect is observed on implantation, clinical pregnancy, live birth and early pregnancy loss rates compared with long GnRH agonist protocol. However, more studies in large numbers of cycles are needed to confirm that increased serum LH level by E(2) pre-treatment during COH has no negative effect on the IVF/ICSI outcomes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19225876      PMCID: PMC2654939          DOI: 10.1007/s10815-009-9300-3

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  17 in total

1.  Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists.

Authors:  Renato Fanchin; Laurent Salomon; Altina Castelo-Branco; François Olivennes; Nelly Frydman; René Frydman
Journal:  Hum Reprod       Date:  2003-12       Impact factor: 6.918

2.  Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.

Authors:  G Borm; B Mannaerts
Journal:  Hum Reprod       Date:  2000-07       Impact factor: 6.918

3.  Luteal estradiol administration strengthens the relationship between day 3 follicle-stimulating hormone and inhibin B levels and ovarian follicular status.

Authors:  Renato Fanchin; João Sabino Cunha-Filho; Luca Maria Schonäuer; Claudia Righini; Dominique de Ziegler; René Frydman
Journal:  Fertil Steril       Date:  2003-03       Impact factor: 7.329

4.  Intraovarian sex steroid hormone interactions and the regulation of follicular maturation: aromatization of androgens by human granulosa cells in vitro.

Authors:  S G Hillier; A M van den Boogaard; L E Reichert; E V van Hall
Journal:  J Clin Endocrinol Metab       Date:  1980-04       Impact factor: 5.958

5.  The number of embryos available for transfer predicts successful pregnancy outcome in women over 39 years with normal ovarian hormonal reserve testing.

Authors:  M S Opsahl; K L Blauer; S H Black; S R Lincoln; L Thorsell; R J Sherins
Journal:  J Assist Reprod Genet       Date:  2001-10       Impact factor: 3.412

6.  GnRH antagonist in assisted reproduction: a Cochrane review.

Authors:  Hesham Al-Inany; Mohamed Aboulghar
Journal:  Hum Reprod       Date:  2002-04       Impact factor: 6.918

7.  Selection of good embryos for transfer depends on embryo cohort size: implications for the 'mild ovarian stimulation' debate.

Authors:  F Devreker; E Pogonici; V De Maertelaer; P Revelard; M Van den Bergh; Y Englert
Journal:  Hum Reprod       Date:  1999-12       Impact factor: 6.918

8.  Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF.

Authors:  E M Kolibianakis; K Zikopoulos; J Schiettecatte; J Smitz; H Tournaye; M Camus; A C Van Steirteghem; P Devroey
Journal:  Hum Reprod       Date:  2004-08-19       Impact factor: 6.918

9.  Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy.

Authors:  Efstratios M Kolibianakis; Carola Albano; Jarl Kahn; Michel Camus; Herman Tournaye; Andre C Van Steirteghem; Paul Devroey
Journal:  Fertil Steril       Date:  2003-04       Impact factor: 7.329

10.  Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation regimens.

Authors:  Renato Fanchin; João Sabino Cunha-Filho; Luca Maria Schonäuer; Isaac Jacques Kadoch; Paul Cohen-Bacri; René Frydman
Journal:  Fertil Steril       Date:  2003-02       Impact factor: 7.329

View more
  17 in total

1.  Abnormally cleaving embryos are able to produce live births: a time-lapse study.

Authors:  Yan Ling Fan; Shu Biao Han; Li Hong Wu; Ya Ping Wang; Guo Ning Huang
Journal:  J Assist Reprod Genet       Date:  2016-01-09       Impact factor: 3.412

2.  Effect of vitrification on mitochondrial membrane potential in human metaphase II oocytes.

Authors:  Cui Chen; Shubiao Han; Weiwei Liu; Yaping Wang; Guoning Huang
Journal:  J Assist Reprod Genet       Date:  2012-08-23       Impact factor: 3.412

3.  Endometrial Receptivity and its Predictive Value for IVF/ICSI-Outcome.

Authors:  A Heger; M Sator; D Pietrowski
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-08       Impact factor: 2.915

4.  Precycle Estradiol in Synchronization and Scheduling of Antagonist Cycles.

Authors:  Shilpa Saple; Mukesh Agrawal; Simi Kawar
Journal:  J Obstet Gynaecol India       Date:  2016-04-29

Review 5.  Luteal phase support for assisted reproduction cycles.

Authors:  Michelle van der Linden; Karen Buckingham; Cindy Farquhar; Jan A M Kremer; Mostafa Metwally
Journal:  Cochrane Database Syst Rev       Date:  2015-07-07

6.  Effects of cumulus cells removal after 6 h co-incubation of gametes on the outcomes of human IVF.

Authors:  Shun Xiong; Wei Han; Jun Xia Liu; Xiao Dong Zhang; Wei Wei Liu; Hong Liu; Guo Ning Huang
Journal:  J Assist Reprod Genet       Date:  2011-09-06       Impact factor: 3.412

7.  Letter to the editor on: "Never too late? Quadruplets at the age of 65 years".

Authors:  Rui-Hong Xue
Journal:  Arch Gynecol Obstet       Date:  2021-11-02       Impact factor: 2.344

8.  Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial.

Authors:  Erik E Hauzman; Azucena Zapata; Alfonso Bermejo; Carlos Iglesias; Antonio Pellicer; Juan A Garcia-Velasco
Journal:  Reprod Biol Endocrinol       Date:  2013-09-28       Impact factor: 5.211

Review 9.  Optimal usage of the GnRH antagonists: a review of the literature.

Authors:  Alan B Copperman; Claudio Benadiva
Journal:  Reprod Biol Endocrinol       Date:  2013-03-15       Impact factor: 5.211

10.  The association of serum estradiol level with outcomes of clomiphene citrate/human menopausal gonadotropin ovarian stimulation for in vitro fertilization and embryo transfer.

Authors:  Xiao-Jin Zhang; Su-Ying Liu; Wei Fu; Xiao-Xi Sun
Journal:  Reprod Biol Endocrinol       Date:  2015-10-06       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.